Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) EBT: 2020-2025

Historic EBT for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to $15.9 million.

  • Tango Therapeutics' EBT rose 154.53% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$100.4 million, marking a year-over-year increase of 18.49%. This contributed to the annual value of -$130.1 million for FY2024, which is 28.03% down from last year.
  • Latest data reveals that Tango Therapeutics reported EBT of $15.9 million as of Q3 2025, which was up 140.89% from -$38.8 million recorded in Q2 2025.
  • Tango Therapeutics' EBT's 5-year high stood at $15.9 million during Q3 2025, with a 5-year trough of -$39.8 million in Q1 2025.
  • For the 3-year period, Tango Therapeutics' EBT averaged around -$26.8 million, with its median value being -$29.1 million (2024).
  • As far as peak fluctuations go, Tango Therapeutics' EBT tumbled by 956,255.93% in 2021, and later soared by 154.53% in 2025.
  • Over the past 5 years, Tango Therapeutics' EBT (Quarterly) stood at -$21.9 million in 2021, then tumbled by 32.65% to -$29.0 million in 2022, then decreased by 5.88% to -$30.7 million in 2023, then declined by 22.48% to -$37.6 million in 2024, then spiked by 154.53% to $15.9 million in 2025.
  • Its last three reported values are $15.9 million in Q3 2025, -$38.8 million for Q2 2025, and -$39.8 million during Q1 2025.